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Elevated plasma LDL (low-density lipoprotein) levels are a major risk factor for developing atherosclerosis and ensuing 
ischemic cardiovascular disease, a leading cause of worldwide 
death. LDL, which is derived by peripheral lipolysis of VLDL 
(very-low-density lipoprotein), is primarily cleared from the 
circulation in the liver via the LDLR (LDL receptor) pathway.1,2 
Hence, plasma LDL levels are determined by the dynamic bal-
ance between hepatic VLDL secretion and LDL clearance.
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VLDL particles are formed by lipidation of apo (apoli-
poprotein) B
100
, the core protein of VLDL, in the endoplas-
mic reticulum and Golgi apparatus.3 The assembly of VLDL 
particles depends on apo B
100
 production and cellular avail-
ability of triglycerides. Accordingly, genetic mutations in apo 
B
100
 are associated with altered VLDL secretion and plasma 
LDL levels.4–6 Overexpression of apo B
100
 results in increased 
VLDL secretion and plasma LDL levels in rabbits.7 Similarly, 
the activity of enzymes involved in de novo lipid biosynthe-
sis also affects VLDL assembly and secretion.8,9 For example, 
impaired loading of triglycerides into nascent VLDL particles, 
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Rationale: An elevated level of plasma LDL (low-density lipoprotein) is an established risk factor for 
cardiovascular disease. Recently, we reported that the (pro)renin receptor ([P]RR) regulates LDL metabolism 
in vitro via the LDLR (LDL receptor) and SORT1 (sortilin-1), independently of the renin–angiotensin system.
Objectives: To investigate the physiological role of (P)RR in lipid metabolism in vivo.
Methods and Results: We used N-acetylgalactosamine modified antisense oligonucleotides to specifically inhibit 
hepatic (P)RR expression in C57BL/6 mice and studied the consequences this has on lipid metabolism. In line 
with our earlier report, hepatic (P)RR silencing increased plasma LDL-C (LDL cholesterol). Unexpectedly, this 
also resulted in markedly reduced plasma triglycerides in a SORT1-independent manner in C57BL/6 mice fed a 
normal- or high-fat diet. In LDLR-deficient mice, hepatic (P)RR inhibition reduced both plasma cholesterol and 
triglycerides, in a diet-independent manner. Mechanistically, we found that (P)RR inhibition decreased protein 
abundance of ACC (acetyl-CoA carboxylase) and PDH (pyruvate dehydrogenase). This alteration reprograms 
hepatic metabolism, leading to reduced lipid synthesis and increased fatty acid oxidation. As a result, hepatic (P)
RR inhibition attenuated diet-induced obesity and hepatosteatosis.
Conclusions: Collectively, our study suggests that (P)RR plays a key role in energy homeostasis and regulation of 
plasma lipids by integrating hepatic glucose and lipid metabolism.  (Circ Res. 2018;122:730-741. DOI: 10.1161/
CIRCRESAHA.117.312422.)
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caused by mutations in the MTP (microsomal triglyceride car-
rier protein), results in defective VLDL secretion.10
Disturbed LDL clearance can increase plasma LDL levels 
and risk for cardiovascular diseases. In line with this, loss-of-
function LDLR mutations are associated with elevated plasma 
LDL levels and cardiovascular risk.11–13 Recently, GWAS stud-
ies have identified single-nucleotide polymorphisms mapping 
to 1p13.3 that strongly associated with plasma LDL levels and 
coronary heart disease.14–19 Subsequent mechanistic studies re-
vealed that SORT1 (sortilin-1), located within the 1p13.3 region, 
is a novel regulator of LDL metabolism.20–22 Overexpression of 
SORT1 increases LDL clearance and decreases plasma LDL lev-
els,16,21,22 whereas SORT1 deficiency reduces cellular LDL up-
take in vitro and LDL clearance in vivo.22,23 In addition, SORT1 
also plays a role in VLDL secretion. Overexpressing SORT1 
promotes ApoB degradation via an endolysosome-dependent 
route and hence reduces VLDL secretion and plasma triglycer-
ide levels.22 Controversially, mice deficient for SORT1 also dis-
play reduced VLDL secretion and triglyceride levels.20,22 These 
opposing results highlight the complex, and not yet fully eluci-
dated, role of SORT1 in lipoprotein metabolism.
The (pro)renin receptor ([P]RR) interacts with renin/prorenin 
(denoted as [pro]renin) at supraphysiological concentrations that 
are even several orders of magnitude higher than (patho)physi-
ological concentrations, questioning the physiological relevance 
of the (P)RR–(pro)renin interaction.24,25 Recently, the (P)RR 
was reported to play a role in Wnt/β-catenin signaling pathway, 
vacuolar H+-ATPase integrity, and T-cell development, indepen-
dently of (pro)renin.26–30 Moreover, we have recently identified 
the (P)RR as a SORT1-interacting protein31 and demonstrated 
that silencing (P)RR expression in hepatocytes in vitro reduces 
protein abundance of SORT1 and LDLR post-transcriptionally, 
and consequently cellular LDL uptake. To understand the role of 
the (P)RR in lipoprotein metabolism in vivo, we studied here the 
consequence of hepatic (P)RR silencing on lipoprotein metabo-
lism. We report that hepatic loss of (P)RR in mice results in a 
SORT1-dependent increase in plasma LDL levels, but unexpect-
edly also in a reduction in plasma triglycerides that was SORT1 
independent that resulted from altered metabolic reprogram-
ming of hepatocytes. Our study thus highlights hepatic (P)RR as 
a crucial regulator of energy and lipid metabolism.
Methods
The authors declare that all supporting data are available within the 
article and its Online Data Supplement. A detailed description of 
methods used in this study is available in the Online Data Supplement.
Results
Inhibiting Hepatic (P)RR Reduced Both Hepatic 
LDL Clearance and VLDL Secretion
We have previously reported that (P)RR inhibition attenu-
ates cellular LDL uptake by reducing LDLR and SORT1 
protein abundance in hepatocytes.31 To understand the role 
of hepatic (P)RR in lipoprotein metabolism in vivo, we 
used N-acetylgalactosamine modified antisense oligonu-
cleotides to inhibit hepatic (P)RR expression. At a dose of 
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Novelty and Significance
What Is Known?
• The (pro)renin receptor ([P]RR) regulates LDL (low-density lipoprotein) 
metabolism in vitro, independent of the renin–angiotensin system.
• Regulation of cellular LDL uptake by the (P)RR is dependent on SORT1 
(sortilin-1) and the LDLR (LDL receptor).
What New Information Does This Article Contribute?
• Inhibiting hepatic (P)RR lowers plasma triglyceride and cholesterol lev-
els in LDLR-deficient mice.
• Hepatic (P)RR inhibition prevents diet-induced obesity, liver steatosis, 
and improves glycemic control.
• Hepatic (P)RR controls the protein abundance of PDH (pyruvate dehy-
drogenase) and ACC (acetyl-CoA carboxylase), thereby promoting fatty 
acid oxidation and reducing lipid synthesis.
Functions of the (P)RR, independent of the renin–angiotensin 
system, are not yet completely understood. Previously, we ob-
served that hepatic (P)RR regulates LDL metabolism in vitro by 
controlling protein abundance of LDLR and SORT1. In this study, 
we evaluated the role of (P)RR in vivo and found that inhibiting 
hepatic (P)RR regulates LDL metabolism, but unexpectedly de-
creases plasma triglycerides as well. These actions are, at least 
in part, a result of decreased lipid synthesis and increase fatty 
acid oxidation in the liver as a result of decreased protein abun-
dance of PDH and ACC. These findings identify (P)RR as a crucial 
regulator of hepatic lipid metabolism and suggest that inhibition 
of hepatic (P)RR may be a potential strategy for treating dyslipid-
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3.0 mg kg−1 wk−1, N-acetylgalactosamine (P)RR antisense 
oligonucleotide (G-[P]RR) potently reduced (P)RR expres-
sion in liver, but had no effects on its expression in other 
major organs, including heart, kidney, intestine, spleen, and 
different adipose tissues (Online Figure IA and IC through 
IF). In line with our previous report, inhibiting the (P)RR 
specifically reduced hepatic LDLR and SORT1 protein lev-
els without affecting their transcript levels (Online Figure 
IB). As a result of reduced hepatic LDLR and SORT1 pro-
tein abundance, (P)RR inhibition elevated plasma choles-
terol levels in normal diet (ND)–fed mice, primarily by 
increasing cholesterol content in IDL (intermediate-density 
lipoprotein)/LDL fractions (Figure 1A and 1B). Because 
plasma LDL-C concentrations reflect the balance between 
hepatic LDL clearance and VLDL secretion, we then inves-
tigated the effects of (P)RR inhibition on LDL clearance 
and hepatic VLDL output. In line with decreased LDLR 
and SORT1, inhibiting hepatic (P)RR led to attenuated 
clearance of injected Dil-labeled human LDL (Figure 1C). 
Unexpectedly, (P)RR inhibition also significantly de-
creased plasma triglyceride concentrations (Figure 1D), a 
finding that could be attributed to reduced hepatic VLDL 
secretion (Figure 1E).
We then asked if silencing (P)RR in hepatocytes could ag-
gravate hypercholesterolemia in C57BL/6 mice fed a high-fat 
diet (HFD). Like in ND-fed mice, 1 week after (P)RR inhibi-
tion, plasma cholesterol levels were 3- to 4- fold higher than 
those measured in N-acetylgalactosamine control antisense 
oligonucleotide (G-control)–injected mice (Figure 2A). This 
elevation was primarily attributed to a marked increase in 
cholesterol content in the IDL/LDL fraction (Figure 2B). 
Notably, (P)RR inhibition also increased cholesterol contents 
in the VLDL fraction and reduced cholesterol contents in the 
HDL (high-density lipoprotein) fraction. Unexpectedly, with-
in 2 weeks, plasma cholesterol levels of G-(P)RR–injected 
mice were normalized and similar to those in the saline-
injected or G-control–injected mice (Figure 2A and 2C; 
Online Figure IG). This contrasts with the sustained increase 
Figure 1. Inhibiting hepatic (pro)renin receptor ([P]RR) induces hypercholesterolemia by reducing hepatic LDL (low-density 
lipoprotein) clearance in normal diet (ND)–fed C57BL/6 mice. Eight-week-old male C57BL/6 mice were injected with either saline 
(blue), G-control (magenta), or G-(P)RR (green) intraperitoneally. Mice were euthanized after 7 days, and blood samples were collected 
for (A) determining circulating levels of cholesterol (n=12–18 per group). Each bar and error represent the mean±SEM; ***P<0.001, or (B) 
pooled plasma samples were loaded on FPLC (fast protein liquid chromatography) for lipoprotein fractionation analysis, and cholesterol 
content in each fraction was determined. C, Seven days after injection, mice (n=6 per group) were injected with 50 μg Dil-labeled human 
LDL. Blood samples were drawn retro-orbitally at the indicated time points, and the Dil-LDL was determined. Each point represents the 
mean±SEM, and the area under curve (AUC) was constructed for each group and used to compare the difference in LDL clearance. 
***P<0.001. D, Blood was collected as in (A) and used to determine plasma triglyceride levels. n=12–18 per group; Each bar and error 
represent the mean±SEM. ***P<0.001. E, Seven days after injection, mice (n=6 per group) were fasted for 6 hours and injected with 
Pluronic F127 to inhibit lipoprotein lipase. Blood samples were drawn retro-orbitally at the indicated time points, and the concentration 
of triglycerides was determined. The mean VLDL (very-low-density lipoprotein) secretion for saline-injected, G-control–injected, or G-(P)
RR–injected mice is 474±16, 460±14, and 342±10 mg/dL·h, respectively. The AUC was calculated for individual mice and used to 
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in plasma cholesterol levels in C57BL/6 mice fed with ND 
(Online Figure IH). Nevertheless, (P)RR inhibition in HFD-
fed mice reduced hepatic LDL clearance and VLDL secretion 
(Figure 2D and 2E). Plasma triglycerides and VLDL triglyc-
erides were both lower in G-(P)RR–injected mice when 
compared with saline or G-control–injected mice (Figure 2F 
and 2G), thus mimicking the pattern seen under ND feeding. 
Importantly, plasma LPL (lipoprotein lipase) activity was not 
affected by hepatic (P)RR inhibition (Figure 2H). This ex-
cludes the possibility that increased triglyceride hydrolysis 
underpins reduced levels of plasma triglycerides in (P)RR-
silenced mice.
Because SORT1 deficiency in vivo reduces VLDL se-
cretions and plasma triglycerides and (P)RR silencing de-
creases SORT1,20,22,31 we wondered if the effect of (P)RR 
inhibition on hepatic lipid output is SORT1 dependent. To 
address this possibility, we studied plasma lipid levels in (P)
RR-silenced mice in which we overexpressed hSORT1 (hu-
man SORT1). Exogenous hSORT1 protein was detected in 
liver, and hSORT1 partially rescued the (P)RR inhibition–
induced LDLR protein reduction (Online Figure II). Given 
that SORT1 itself is a clearance receptor for LDL,20–22 it is 
not surprising that hSORT1 overexpression reversed the (P)
RR inhibition–induced increase in plasma cholesterol levels, 
Figure 2. Inhibiting hepatic (pro)renin receptor ([(P]RR) does not result in hypercholesterolemia in high-fat diet (HFD)–fed C57BL/6 
mice. Eight-week-old male C57BL/6 mice were injected with either saline (blue), G-control (magenta), or G-(P)RR (green), and fed an 
HFD for 4 weeks. A, Plasma cholesterol concentrations were determined weekly, and each point represents the mean±SEM. n=10 per 
group; ***P<0.001; G-control vs G-(P)RR. B, C, Pooled plasma samples were collected after the (B) first week of diet, or (C) after 4 weeks 
of diet, and the lipoprotein distribution was determined. The cholesterol content in each fraction was determined and is plotted. D, Two 
weeks after start of HFD diet, mice (n=6 per group) were injected with 50 μg Dil-labeled human LDL, and LDL clearance was assessed. 
Each point represents the mean±SEM, and the area under curve (AUC) was constructed for each treatment and used to compare the 
differences in LDL (low-density lipoprotein) clearance. *P<0.05. E, Two weeks after (P)RR inhibition, mice were fasted for 6 hours, and 
VLDL (very-low-density lipoprotein) secretion was assessed (n=6 per group) by injecting mice with Pluronic F127 to inhibit lipoprotein 
lipase. Blood samples were drawn retro-orbitally at the indicated time points, and the concentration of triglycerides was determined, 
and the AUC was calculated and used to compare the differences in the rate of VLDL secretion. **P<0.01; G-control vs G-(P)RR. F, G, 
Plasma triglyceride levels were analyzed in samples collected after 4 weeks of HFD. Each bar represents the mean±SEM, n=10 per group. 
***P<0.001, or (G) pooled plasma samples were analyzed by FPLC (fast protein liquid chromatography). H, Plasma LPL (lipoprotein lipase) 
activity was determined for mice were injected with G-control or G-(P)RR and fed HFD for 4 weeks. n=9 per group. HDL indicates high-
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primarily by decreasing the cholesterol content in the VLDL 
and IDL/LDL fractions (Figure 3A and 3B). However, 
hSORT1 overexpression did not prevent the reduction in 
plasma triglycerides caused by (P)RR inhibition (Figure 3C), 
implying that (P)RR inhibition reduced plasma triglycerides 
in a SORT1-independent manner.
Hepatic (P)RR Inhibition Reduced Plasma 
Cholesterol Levels in LDLR-Deficient Mice
As (P)RR affects both hepatic LDL clearance and VLDL 
secretion, it is possible that (P)RR has a differential role in 
governing plasma cholesterol levels under distinct diet condi-
tions. Under ND, LDL clearance may govern plasma cho-
lesterol levels, whereas under HFD, VLDL secretion may 
become more prominent in determining plasma cholesterol 
levels. To address this issue, we tested the effects of hepatic 
(P)RR inhibition on plasma cholesterol levels in mice with 
impaired LDL clearance by injecting adeno-associated virus 
expressing the gain-of-function PCSK9 (proprotein conver-
tase subtilisin/kexin type 9) D377Y mutant32,33 and in LDLR−/− 
mice. As expected, injecting C57BL/6 mice with the PCSK9 
D377Y–encoding adeno-associated virus led to a marked in-
crease in the circulating levels of LDL-C (from 76.74±1.72 
to 167.3±2.27 mg/dL, n=39). We subsequently injected these 
mice with either saline, G-control, or G-(P)RR for 4 weeks 
and fed either ND or HFD. We found that after this treatment 
period, (P)RR inhibition reduced plasma cholesterol levels 
in both ND- and HFD-fed mice, despite the lack of func-
tional LDLR-mediated clearance (Figure 4A through 4D). 
Similarly, inhibiting hepatic (P)RR in LDLR−/− mice induced 
a sustained decrease in plasma cholesterol levels independent 
of diet (Online Figure IIIA and IIIB). These results confirm 
that LDL clearance is more dominant than VLDL secretion in 
determining circulating LDL levels in mice fed ND. Similar 
to the observation in wild-type C57BL/6 mice, plasma tri-
glycerides and VLDL-associated triglycerides were reduced 
by (P)RR inhibition under ND or HFD feeding (Figure 4E 
through 4H), in PCSK9-induced LDLR-deficient mice. 
Moreover, in LDLR−/− mice, hypertriglyceridemia was pre-
vented by hepatic (P)RR inhibition (Online Figure IIIC and 
IIID). We reasoned that if (P)RR inhibition primarily affects 
lipid export pathways, we should observe lipid accumulation 
in liver, especially under HFD feeding. However, we found 
that hepatic lipid levels were also reduced by (P)RR inhibi-
tion (Figure 4I through 4K; Online Figure IV), implying that 
the reduced plasma lipid levels are not the result of impaired 
lipid secretion.
Hepatic (P)RR Inhibition Attenuated Diet-Induced 
Obesity and Improved Metabolic Disorders
(P)RR inhibition resulted in decreased hepatic VLDL secre-
tion without concomitant hepatic lipid accumulation. This 
could point toward (P)RR regulating hepatic lipid biosyn-
thesis, an important facet of fatty liver disease and obesity.34 
We therefore questioned whether hepatic (P)RR inhibition 
can ameliorate diet-induced fatty liver disease and obesity. 
To address this, we inhibited hepatic (P)RR expression in 
C57BL/6 mice fed an HFD for 14 weeks. In line with our 
hypothesis, loss of hepatic (P)RR attenuated diet-induced 
obesity in C57BL/6 mice (Figure 5A). Body composition 
analyses using EchoMRI revealed that inhibiting hepatic 
(P)RR lowered fat weight of the mice, but did not affect 
the weight of lean mass (Figure 5B; Online Figure VA). 
Furthermore, the size of the livers and white adipose tis-
sues of G-(P)RR–injected mice were smaller than control 
mice (Figure 5C and 5D). Under HFD, lipid accumulates 
in liver and increases liver weight. Mean liver weight of 
saline-injected or G-control–injected mice was ≈2 g, which 
was nearly twice the mean liver weight (1.07±0.02 g; n=12; 
P<0.001) of ND-fed C57BL/6 mice at same age (22 weeks 
Figure 3. SORT1 (sortilin-1) overexpression prevents PRR-
dependent hypercholesterolemia, but does not affect 
reduction in plasma triglycerides. Eight-week-old male C57BL/6 
mice were injected with G-control or G-(pro)renin receptor ([P]
RR) intraperitoneally and subsequently injected with either 
adenovirus carrying GFP (green fluorescent protein; Ad-GFP) or 
adenovirus carrying human SORT1 (Ad-SORT1) via the tail vein. 
Mice were fed with normal diet (ND) or high-fat diet (HFD) for 1 
week and (A) plasma cholesterol levels were determined. Each bar 
represents the mean±SEM (n=6 per group). **P<0.01; ***P<0.001. 
Alternatively, (B) lipoprotein composition in pooled plasma samples 
was analyzed by fractionation. C, Plasma was collected as in (A) 
and analyzed for triglyceride content. Each bar and error represent 
the mean±SEM (n=6 per group). **P<0.01. HDL indicates high-
density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-
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old). Hepatic (P)RR inhibition attenuated HFD-induced 
liver weight gain and prevented abnormal lipid deposition 
in the liver (Figure 5E and 5F). Liver/body weight ratios of 
G-(P)RR–injected mice were also significantly lower than 
that of G-control–injected mice and resembled the ratio of 
ND-fed C57BL/6 mice at the same age (Online Figure VB). 
Moreover, mice in which hepatic (P)RR was inhibited had 
smaller adipocytes in inguinal white adipose tissues (Online 
Figure VC), but normal brown adipose tissues weight 
(Figure 5D). In agreement with reduced adipose tissues, 
plasma leptin concentrations were also reduced by hepatic 
(P)RR inhibition (Online Figure VD). However, plasma 
adiponectin concentrations were unaltered by (P)RR inhibi-
tion despite the marked reduction in adipose tissue weight 
(Online Figure VE), likely because of increased expression 
of adiponectin in white adipose tissues (Online Figure IC 
and IE). This suggests that hepatic (P)RR inhibition can 
indirectly affect adipokine secretion by adipose tissues, 
thereby contributing to improved metabolic control.
Accompanied by less body weight gain, fasting blood glu-
cose concentrations were reduced by (P)RR inhibition (Online 
Figure VF), which also improved glucose tolerance and low-
ered plasma insulin levels (Online Figure VG and VH). Plasma 
AST (aspartate aminotransferase), ALT (alanine aminotrans-
ferase), and AST/ALT ratio indicate that (P)RR inhibition did 
not cause liver damage (Online Figure VI). In addition, H&E 
(hematoxylin and eosin) staining also revealed improved liver 
morphology by (P)RR inhibition (Figure 5E). Cumulative food 
intake of the mice during the 14-week experimental period was 
also recorded. G-(P)RR–injected mice consumed slightly less 
food than saline or G-control–injected mice, but when correct-
ed for their body weight, their food consumption was actually 
higher (Online Figure VJ), suggesting that the reduced body 
weight gain is not because of reduced food intake. In addition, 
Figure 4. Hepatic (pro)renin receptor ([P]RR) inhibition in the absence of LDLR (low-density lipoprotein receptor) reduces plasma 
lipid levels and hepatic lipid deposition. Eight-week-old male C57BL/6 mice were injected intraperitoneally with 10×1010 genomic 
copies of mouse PCSK9 (proprotein convertase subtilisin/kexin type 9) D377Y adeno-associated virus (AAV), and fed with normal diet 
(ND) for 4 weeks. Subsequently, mice were injected with either saline (blue), G-control (magenta), or G-(P)RR (green) and fed with ND or 
high-fat diet (HFD) for an additional 4 weeks. A–D, Plasma cholesterol levels and lipoprotein profiles at the end of study were determined 
for ND-fed (A, B) and HFD-fed (C, D) mice. E–H, Plasma triglycerides and lipoprotein distribution were determined for ND-fed (E, G) 
and HFD-fed (F, H) mice. (n=6 per group.) **P<0.01; ***P<0.001; G-control vs G-(P)RR. I, Representative images of Oil Red O–stained 
liver samples from above-indicated mice fed with ND or HFD for 4 weeks. Scale bar=100 μm. J, K, Lipids were extracted from liver 
samples and analyzed for triglycerides and cholesterol levels. *P<0.05; G-control vs G-(P)RR. HDL indicates high-density lipoprotein; IDL, 
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we did not observe any difference in blood pressure or heart 
rate among saline-injected, G-control–injected, or G-(P)RR–
injected mice (Online Figure VK and VL), suggesting that the 
activity of the autonomic nervous system was not affected. We 
then monitored oxygen consumption and physical activity of 
the mice using metabolic cages. Inhibiting hepatic (P)RR in-
creased oxygen consumption and 24-hour respiratory quotient 
of the mice, implying increased catabolism of energy sources 
(Figure 5G). Yet, physical activities of the mice were not differ-
ent (Online Figure VM). Collectively, these results support the 
beneficial metabolic effects of (P)RR inhibition.
Inhibiting the (P)RR Upregulated Genes Involved in 
Fatty Acid Oxidation
Currently recognized functions of the (P)RR are not linked with 
lipid biosynthesis and energy homeostasis. To understand how 
(P)RR may regulate these processes, we transcriptionally profiled 
mice after (P)RR inhibition. Male mice (8 weeks old) were in-
jected with either saline or G-(P)RR for 5 days, and liver samples 
were collected and extracted for total RNA and RNAseq analysis. 
We identified that (P)RR inhibition led to up- and downregula-
tion of 199 genes and 202 genes, respectively (Online Table III). 
Gene ontology enrichment analysis revealed that metabolic path-
ways, including fatty acid (FA) degradation and elongation, were 
strongly affected by (P)RR inhibition (Online Figure VIA and 
VIB). Among the affected genes, several genes involved in FA 
β-oxidation, such as Hadha, Acaa2, Acadvl, and Acadl, were up-
regulated by (P)RR inhibition, as confirmed by quantitative poly-
merase chain reaction (Online Figure VII). As such, increased FA 
β-oxidation may contribute to increased oxygen consumption 
and reduced hepatic lipid content.
Inhibiting (P)RR Reduced Protein Abundance of 
ACC and PDH
To complement the RNA sequencing analysis and to better 
understand the function(s) of the (P)RR, we next performed 
comparative quantitative proteomics to identify hepatic pro-
teins which are affected by (P)RR inhibition. Through this 
unbiased approach, we identified 191 and 116 proteins that 
were down- and upregulated, respectively, after (P)RR inhibi-
tion during feeding of either ND or HFD (Online Table IV). 
As reported previously, LDLR protein abundance was de-
creased by (P)RR inhibition (Online Table IV), validating the 
effectiveness of this approach to identify proteins with altered 
abundance. Gene ontology enrichment analyses revealed that 
proteins involved in lipid biosynthesis, lipid metabolism, and 
cholesterol metabolism were markedly affected by (P)RR in-
hibition (Online Figure VIC and VID). Among the identified 
proteins, PDH (pyruvate dehydrogenase), ACCα (acetyl-CoA 
carboxylase α), and ACCβ were markedly decreased. PDH is 
the enzyme responsible for converting pyruvate to acetyl-CoA 
and is a central metabolic node.35 ACC catalyzes the forma-
tion of malonyl-CoA, an essential substrate for FA synthesis 
and a potent inhibitor of FA oxidation.36 ACC is crucial in 
determining lipid storage and overall energy metabolism.37 
Thus, reduced PDH and ACC may contribute to increased FA 
oxidation and decreased lipid synthesis. To confirm this, we 
examined ACCα/β and PDH protein abundance in the liver 
of saline-injected, G-control–injected, or G-(P)RR–injected 
C57BL/6 mice fed with HFD for 14 weeks. Corroborating the 
proteomic-based approach, hepatic ACCα/β, PDHA  (pyruvate 
dehyrogenase E1 component subunit α), and PDHB (pyruvate 
Figure 5. Hepatic (pro)renin receptor ([P]RR) inhibition attenuates diet-induced obesity and metabolic dysregulation. Eight-week-old 
mice were injected with saline (blue), G-control (magenta), or G-(P)RR (green) and fed a high-fat diet (HFD) for 14 weeks. (n=10 per group.) A, 
Body weight was monitored during the study period and each point and error represent the mean±SEM. ***P<0.001. Representative picture 
showing that G-(P)RR–injected mice are leaner than control mice. B, Fat and lean mass were measured by EchoMRI. Each bar and error 
represent the mean±SEM. ***P<0.001. C, Liver weight, and representative pictures showing G-(P)RR–treated mice have less fatty liver. **P<0.01. 
D, Weight and representative picture of different adipose tissue depots. Brown fat tissue of saline and G-control–injected mice were surrounded 
with white fat which was removed to give a correct estimation of the weight of the brown fat. ***P<0.001. E, Representative images of Oil Red 
O (ORO) and H&E (hematoxylin and eosin) staining of the livers (scale bar=200 μm). F, Hepatic lipids were extracted and measured. *P<0.05; 
G-control vs G-(P)RR. G, Oxygen consumption and 24-h average respiratory quotient (RQ) of G-control–injected and G-(P)RR–injected mice 
was monitored with a metabolic monitoring system 4 days before euthanize. n=8 per group. BAT indicates brown adipose tissue; eWAT, 
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dehydrogenase E1 component subunit β) were reduced by 
≈40% to 60% after hepatic (P)RR inhibition (Figure 6A), 
whereas the transcript abundance of ACCα/β, PDHA, and 
PDHB remained unaltered (Online Figure VII). Inhibiting 
the (P)RR in human hepatoma HepG2 cells with siRNAs also 
reduced protein abundances of ACCα/β, PDHA, and PDHB 
(Online Figure VIIIA), suggesting that this outcome is con-
served in both mouse and humans. The (P)RR knockdown–
induced reduction in ACCα/β protein abundance was partially 
reversed by the lysosome inhibitor bafilomycin A1, but was 
not affected by the autophagy inhibitor 3-methyladenine or 
the proteasome inhibitor MG-132 (Online Figure VIIIB), 
suggesting accelerated lysosome-dependent degradation of 
ACCα/β by (P)RR inhibition. In contrast, bafilomycin A1, 
3-methyladenine, and MG-132 were unable to rescue (P)RR 
knockdown–induced reduction in PDHA and PDHB, imply-
ing that a different mechanism underlies the control of these 
proteins by (P)RR.
(P)RR Inhibition Reduced Cellular Acetyl-CoA 
Abundance and FA Synthesis in Hepatocytes
Collectively, our results suggest that by reducing protein 
abundance of PDH, (P)RR inhibition reduces pyruvate to 
acetyl-CoA conversion and therefore reduces cellular ace-
tyl-CoA production from glucose. Lower cellular acetyl-
CoA levels will limit cellular FA and cholesterol synthesis. 
This biosynthetic block will be compounded by reduced 
ACC abundance, which will further limit FA synthesis. To 
test this hypothesis, we first measured relevant hepatic me-
tabolites in mice injected with saline, G-control, or G-(P)
RR and fed with HFD for 14 weeks. As expected, G-(P)
RR–injected mice displayed hepatic pyruvate accumulation 
(Figure 6B), increased plasma pyruvate and lactate concen-
trations (Figure 6C and 6D), and decreased hepatic PDH 
activity (Figure 6E). Nevertheless, despite these changes, 
hepatic acetyl-CoA concentrations were unaltered by (P)RR 
inhibition (Figure 6F). Yet importantly, cellular acetyl-CoA 
Figure 6. Inhibiting the (pro)renin receptor ([P]RR) reduces PDH (pyruvate dehydrogenase) and ACC (acetyl-CoA carboxylase) 
protein abundance and activity. A, Representative blot of liver samples from mice injected with saline, G-control, or G-(P)RR, and fed 
a high-fat diet (HFD) for 14 weeks. The protein abundance of PDHA (pyruvate dehyrogenase E1 component subunit α), PDHB (pyruvate 
dehydrogenase E1 component subunit β), and ACCα/β was quantified and normalized to the level of β-actin in the same lysate. (n=6 
per group); *P<0.05; ***P<0.001. B, C57BL/6 mice were treated with antisense oligonucleotides (ASOs) and fed with HFD for 14 weeks. 
Hepatic pyruvate concentrations (B), plasma pyruvate concentrations (C), plasma lactate concentrations (D), hepatic PDH activity (E), and 
acetyl-CoA concentrations (F) were determined. G, Mouse primary hepatocytes were treated with G-control or G-(P)RR for 36 hours, and 
cellular Acetyl-CoA concentrations were determined. Three independent experiments in triplicates were performed. ***P<0.001. Oxygen 
consumption rate (OCR; H) and fuel dependency (I) were measured in mouse primary hepatocytes treated with G-control or G-(P)RR for 
36 hours. Arrow 1 to 3 indicates addition of oligomycin, FCCP (carbonyl cyanide-4-[trifluoromethoxy]phenylhydrazone) and the mixture of 
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levels in isolated mouse primary hepatocytes in which (P)RR 
was inhibited using G-(P)RR antisense oligonucleotide were 
reduced (Figure 6G). Similarly, acetyl-CoA levels were de-
creased by (P)RR inhibition in HepG2 cells, combined with 
a decrease in cellular PDH activity, increased cellular pyru-
vate concentrations and medium lactate concentrations, and 
reduced cellular lipid levels (Online Figure VIIIC through 
VIIIG). These data support our hypothesis and simultane-
ously suggest that in vivo, alternative sources, especially FAs 
supply, are available to overcome reduced pyruvate to acetyl-
CoA conversion. This may also explain why acetyl-CoA lev-
els were not reduced in the liver, as they were in HepG2 cells 
and primary hepatocytes. It is plausible that increased FA 
oxidation provides additional acetyl-CoA to compensate the 
increased energetic demand, which could also explain the in-
creased oxygen consumption observed in G-(P)RR–injected 
mice. Therefore, we examined if (P)RR inhibition affects the 
oxygen consumption rate in mouse primary hepatocytes and 
HepG2 cells. As expected, inhibiting the (P)RR significantly 
increased basal oxygen consumption rate by ≈50% in mouse 
primary hepatocytes (Figure 6G) and ≈30% in HepG2 cells 
(Online Figure VIIIH), and implying increased energy expen-
diture and utilization of high oxygen–consuming fuels such 
as FA. To fully understand the mechanism, we further ex-
amined cellular fuel dependency on long-chain FA in mouse 
primary hepatocytes and HepG2 cells. In the presence of 50 
µmmol/L oleic acid, long-chain FA accounted for ≈20% to 
30% oxidized fuels (glucose, glutamine, and long-chain FA 
together) in control cells, whereas it accounted for >40% oxi-
dized fuels in primary mouse hepatocytes and HepG2 cells 
with (P)RR inhibited (Figure 6H; Online Figure VIIII). These 
data suggest that reduced acetyl-CoA supply from pyruvate 
is compensated by increased FA oxidation, as a mechanism to 
sustain cellular energy needs.
Discussion
We recently reported that the (P)RR is a novel modulator of 
LDL metabolism in vitro.31 In the current study, we demon-
strate that also in vivo, inhibiting the (P)RR in hepatocytes 
leads to defective LDL clearance as a result of reduced 
SORT1 and LDLR protein abundance. SORT1 is a recently 
identified hepatic clearance receptor for LDL, which also 
regulates VLDL secretion and plasma triglycerides.16,20–22,38 
SORT1 deficiency reduces VLDL secretion and plasma tri-
glycerides,20 and in line with this, we found that (P)RR in-
hibition reduced VLDL secretion and plasma triglycerides, 
likely as a consequence of reduced SORT1. However, hepatic 
overexpression of hSORT1 in mice with (P)RR silencing was 
unable to prevent the reduction in plasma triglycerides, de-
spite completely preventing the increase in plasma LDL-C. 
This implies that the (P)RR regulates plasma triglycerides 
via a SORT1-independent manner. Furthermore, plasma 
LPL activity was not affected by (P)RR inhibition, exclud-
ing the possibility that increased triglyceride hydrolysis ac-
counts for the reduced plasma triglycerides. In fact, hepatic 
lipid concentrations, including triglycerides and cholesterol, 
were both markedly reduced by (P)RR inhibition, indicating 
that lipid synthesis is diminished. Indeed, we found that the 
protein abundance of ACC, the crucial enzyme catalyzing the 
first step in FA synthesis, was markedly reduced by (P)RR 
inhibition. As a consequence, limited amounts of lipid be-
ing available for ApoB lipidation likely caused the reduction 
in plasma triglycerides. This may also explain why (P)RR 
inhibition even reduced plasma cholesterol levels in LDLR-
deficient mice, in whom SORT1-dependent LDL clearance 
is impaired.
Our results raise the question of how the (P)RR regulates 
cellular lipid levels. Intriguingly, vacuolar H+-ATPase has re-
cently been identified as a component of the mTORC1 (mech-
anistic target of rapamycin complex 1) pathway.39 Indeed, 
acidification of lysosomes by vacuolar H+-ATPase is crucial 
for mTOR activation and function.40 Increased mTORC1 
activity is observed in genetic and HFD-induced obesity 
and has been implicated in the regulation of lipogenesis and 
VLDL secretion.41–43 Knocking down the (P)RR reduces the 
protein levels of several subunits of the vacuolar H+-ATPase 
complex.28–30,44 Consequently, (P)RR inhibition may prevent 
mTORC1 activation. Nevertheless, this seems unlikely as a 
recent report found that mTORC1 signaling was unaffected 
by (P)RR.45
An alternative explanation for the effect of (P)RR on he-
patic lipid metabolism may be related to the renin–angio-
tensin system, which has been linked with obesity and lipid 
metabolism.46 However, this too seems unlikely, as the affin-
ity of (P)RR to (pro)renin is very low, and in fact, their in-
teraction requires supraphysiological concentrations of (pro)
renin. Rather, by using a combined unbiased transcriptome 
and proteomic approach, we now identified PDH and ACC 
as downstream effectors of (P)RR inhibition. (P)RR inhibi-
tion has previously been reported to reduce PDHB protein 
levels via a tyrosine-phosphorylation–dependent manner in 
mouse retina and human retinal pigment epithelium cells.47 
We found that both PDHA and PDHB were reduced by (P)
RR inhibition. PDH is a ubiquitously expressed enzyme 
complex that catalyzes the conversion of pyruvate to acetyl-
CoA,48,49 acting as a central node that links lipid metabolism, 
glucose metabolism, and the tricarboxylic acid cycle. We 
thus speculated that by reducing PDH protein abundance and 
activity, (P)RR inhibition would reduce acetyl-CoA produc-
tion from glucose and consequently diminish FA synthesis 
and increase FA oxidation (Figure 7).50 Indeed, this is what 
we observe in the livers of (P)RR-silenced mice. In addi-
tion, (P)RR inhibition also reduced ACC protein abundance. 
ACC plays an essential role in regulating FA synthesis and 
degradation.37 Genetic deletion, or inhibition, of ACC reduc-
es body weight gain and fat mass, suppresses triglycerides 
synthesis, and increases FA oxidation and energy expen-
diture,51,52 which resembles the phenotype of hepatic (P)
RR inhibition. Moreover, PPARγ (peroxisome proliferator-
activated receptor gamma) expression was reduced by (P)
RR inhibition by ≈50% (Online Figure VII), and this may 
also have contributed to the reduced hepatic lipogenesis, as 
hepatic PPARγ plays important roles in HFD-induced up-
regulation of lipogenic genes and de novo lipogenesis.53–55 
Recent studies have reported that genetically deleting adi-
pose (P)RR in mice resulted in resistance to diet-induced 
obesity56 and accelerated oxygen consumption,57 yet causing 
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white adipose tissues and brown adipose tissues excluded the 
possibility that adipose (P)RR deficiency also contributed to 
the observed phenotype in our study. However, it raises the 
question whether inhibiting the (P)RR in both adipose tissue 
and liver would provide additional beneficial effects in treat-
ing metabolic disorders.
Post-transcriptional regulation of ACC and PDH is not 
well understood, and thus, novel studies are required to fully 
understand their protein degradational regulation and the role 
of the (P)RR in this process. TRB3 (tribbles-related protein 
3) has been reported to control ACC degradation under fast-
ing conditions by coupling ACC to the E3 ligase COP1 (con-
stitutive photomorphogenic protein 1).58 Interestingly, (P)RR 
inhibitions upregulated the expression of several E3 ligases, 
including HECTD1 (HECT domain E3 ubiquitin protein li-
gase 1; Online Table III), and both ACCα and ACCβ have 
been reported to interact with HECTD1.59 It is therefore con-
ceivable that (P)RR inhibition accelerates ACC degradation 
Figure 7. Model for reprogrammed hepatic metabolism by (pro)renin receptor ([P]RR) inhibition. Inhibiting hepatic (P)RR reduces 
PDH (pyruvate dehydrogenase) activity, impairing pyruvate metabolism and reducing acetyl-CoA supply from pyruvate, which limits fatty 
acid (FA) biosynthesis. (P)RR inhibition further limits FA biosynthesis by reducing protein abundance of ACC (acetyl-CoA carboxylase), the 
crucial enzyme in FA biosynthesis. It further signals to increase FA oxidation via reduced malonyl-CoA, an inhibitor of FA oxidation that 




 http://ahajournals.org by on Septem
ber 12, 2018
740  Circulation Research  March 2, 2018
via lysosomes by upregulating HECTD1. Simultaneously, 
the (P)RR inhibition–induced reduction in PDH abundance is 
more difficult to understand. Inhibiting either autophagy, the 
lysosome or the proteasome, did not rescue this reduction, nor 
did inhibit mitophagy, a special form of autophagy involved in 
degradation of mitochondrial proteins (data not shown). This 
may suggest that (P)RR inhibition regulates PDH abundance 
via an as yet unsolved mechanism, as seems to be the case 
with SORT1 as well.31
In conclusion, we report that hepatic (P)RR is a cru-
cial regulator of lipid metabolism. Inhibiting hepatic (P)
RR reduced ACC and PDH protein levels and consequently 
increases FA oxidation and reduces lipid synthesis, thus at-
tenuating diet-induced obesity and liver steatosis, as well 
as improving glycemic controls in C57BL/6 mice. Taken 
together, our study highlights the potential of inhibit-
ing hepatic (P)RR as a therapeutic treatment for meta-
bolic disorders such as fatty liver diseases and familial 
hypercholesterolemia.
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